Person:
AYDIN, MEHMET AKİF

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

AYDIN

First Name

MEHMET AKİF

Name

Filters

2018 - 20203
Reset filters

Settings

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Publication
    Demographic and clinical characteristics of rapidly progressive glomerulonephritis in Turkey
    (Oxford Univ Press, 2020-06-01) Aydın, Zeki; Türkmen, Kultiğin; Dede, Fatih; Yaşar, Emre; Öztürk, Savaş; Tatar, Erhan; Şahin, Garip; Şahin, Gülizar Manga; Oto, Özgür Akın; Sumnu, Abdullah; Eroğlu, Eray; Dinçer, Mevlüt Tamer; Dursun, Belda; Eren, Necmi; Sevinç, Mustafa; Güzel, Fatma Betül; Yalın, Serkan Feyyaz; Kutlay, Sim; Apaydın, Süheyla; Berktaş, Hacı Bayram; Kazan, Sinan; Dheir, Hamad; Bora, Feyza; Baştürk, Taner; Şahin, İdris; Aydin, Mehmet; AYDIN, MEHMET AKİF; Tıp Fakültesi; Nefroloji Ana Bilim Dalı; 0000-0002-5665-7402; AAJ-8220-2020
  • No Thumbnail Available
    Publication
    Morning blood pressure surge in early autosomal dominant polycystic kidney disease and its relation with left ventricular hypertrophy
    (Oxford Univ Press, 2018-05-01) Yıldız, Abdulmecit; Sağ, Saim; Gül, Cuma; Can, Fatma; Oruç, Aysegül; Aydın, Mehmet; Bedir, Ömer; Akgür, Suat; Ayar, Yavuz; Güllülü, Sürneyye; Güllülü, Mustafa; Ersoy, Alparslan; YILDIZ, ABDULMECİT; Can, Fatma; ORUÇ, AYŞEGÜL; AYDIN, MEHMET AKİF; Bedir, Ömer; AKGÜR, SUAT; Ayar, Yavuz; GÜLLÜLÜ, NAZMİYE SÜMEYYE; GÜLLÜLÜ, MUSTAFA; ERSOY, ALPARSLAN; Tıp Fakültesi; Dahiliye Bölümü; 0000-0003-2467-9356; 0000-0002-0342-9692; 0000-0002-5665-7402; 0000-0003-4607-9220; 0000-0002-5665-7402; AGF-0767-2022; GSE-0029-2022; AAH-5054-2021; AAH-4002-2021; O-9948-2015; HIG-9032-2022; IBQ-9926-2023; AAJ-8220-2020; IVE-3975-2023; EJA-1761-2022; EWD-8403-2022; JGS-9425-2023
  • No Thumbnail Available
    Publication
    Demographic, clinical and laboratory characteristics of rapidly progressive glomerulonephritis in Turkey: Turkish Society of Nephrology-Glomerular Diseases (TSN-GOLD) Working Group
    (Springer, 2020-09-29) Aydın, Zeki; Türkmen, Kültigin; Dede, Fatih; Yaşar, Emre; Öztürk, Savaş; Aydın, Mehmet; Tatar, Erhan; Şahin, Garip; Manga, Gülizar; Oto, Özgür; Şumnu, Abdullah; Eroğlu, Eray; Dinçer, Tamer; Dursun, Belda; Eren, Necmi; Sevinç, Mustafa; Güzel, Fatma Betül; Yalın, Serkan; Kutlay, Sim; Apaydın, Süheyla; Berktaş, Hacı Bayram; Kazan, Sinan; Dheir, Hamad; Bora, Feyza; Baştürk, Taner; Sahin, Idris; AYDIN, MEHMET AKİF; Tıp Fakültesi; Dahiliye Ana Bilim Dalı; Nefroloji Bilim Dalı; 0000-0002-5665-7402; AAJ-8220-2020
    Background In our study, diagnostic and demographic characteristics of patients diagnosed with RPGN by biopsy, clinical and laboratory findings in our country were investigated. Methods Data were obtained from the Turkish Society of Nephrology Glomerular Diseases (TSN-GOLD) Working Group database. Demographic characteristics, indications for biopsy, diagnosis of the glomerular diseases, comorbidities, laboratory and biopsy findings of all patients were recorded. According to their types, RPGN patients were classified as type 1 (anti-GBM related), type 2 (immuncomplex related) and type 3 (pauci-immune). Results Of 3875 patients, 200 patients with RPGN (mean age 47.9 +/- 16.7 years) were included in the study which constitutes 5.2% of the total glomerulonephritis database. Renal biopsy was performed in 147 (73.5%) patients due to nephritic syndrome. ANCA positivity was found in 121 (60.5%) patients. Type 1 RPGN was detected in 11 (5.5%), type 2 RPGN in 42 (21%) and type 3 RPGN in 147 (73.5%) patients. Median serum creatinine was 3.4 (1.9-5.7) mg/dl, glomerular filtration rate was 18 (10-37) ml/min/1.73m(2)and proteinuria 2100 (1229-3526) mg/day. The number of crescentic glomeruli ratio was ratio 52.7%. It was observed that urea and creatinine increased and calcium and hemoglobin decreased with increasing crescentic glomerular ratio. Conclusions Our data are generally compatible with the literature. Advanced chronic histopathological findings were prominent in the biopsy of 21 patients. Early biopsy should be performed to confirm the diagnosis of RPGN and to avoid unnecessary intensive immunosuppressive therapy. In addition to the treatments applied, detailed data, including patient and renal survival, are needed.